5 results on '"Musella, Alessandra"'
Search Results
2. Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis
- Author
-
Stampanoni Bassi, Mario, Iezzi, Ennio, Marfia, Girolama A., Simonelli, Ilaria, Musella, Alessandra, Mandolesi, Georgia, Fresegna, Diego, Pasqualetti, Patrizio, Furlan, Roberto, Finardi, Annamaria, Mataluni, Giorgia, Landi, Doriana, Gilio, Luana, Centonze, Diego, and Buttari, Fabio
- Published
- 2018
- Full Text
- View/download PDF
3. Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake.
- Author
-
Gentile, Antonietta, Musella, Alessandra, De Vito, Francesca, Fresegna, Diego, Bullitta, Silvia, Rizzo, Francesca Romana, Centonze, Diego, and Mandolesi, Georgia
- Subjects
- *
GLUTAMIC acid , *MULTIPLE sclerosis treatment , *GLUTAMATE transporters , *NEUROPROTECTIVE agents , *DRUG side effects , *ANTI-inflammatory agents - Abstract
Background: Laquinimod is an immunomodulatory drug under clinical investigation for the treatment of the progressive form of multiple sclerosis (MS) with both anti-inflammatory and neuroprotective effects. Excitotoxicity, a prominent pathophysiological feature of MS and of its animal model, experimental autoimmune encephalomyelitis (EAE), involves glutamate transporter (GluT) dysfunction in glial cells. The aim of this study was to assess whether laquinimod might exert direct neuroprotective effects by interfering with the mechanisms of excitotoxicity linked to GluT function impairments in EAE.Methods: Osmotic minipumps allowing continuous intracerebroventricular (icv) infusion of laquinimod for 4 weeks were implanted into C57BL/6 mice before EAE induction. EAE cerebella were taken to perform western blot and qPCR experiments. For ex vivo experiments, EAE cerebellar slices were incubated with laquinimod before performing electrophysiology, western blot, and qPCR.Results: In vivo treatment with laquinimod attenuated EAE clinical score at the peak of the disease, without remarkable effects on inflammatory markers. In vitro application of laquinimod to EAE cerebellar slices prevented EAE-linked glutamatergic alterations without mitigating astrogliosis and inflammation. Moreover, such treatment induced an increase of Slcla3 mRNA coding for the glial glutamate-aspartate transporter (GLAST) without affecting the protein content. Concomitantly, laquinimod significantly increased the levels of the glial glutamate transporter 1 (GLT-1) protein and pharmacological blockade of GLT-1 function fully abolished laquinimod anti-excitotoxic effect.Conclusions: Overall, our results suggest that laquinimod protects against glutamate excitotoxicity of the cerebellum of EAE mice by bursting the expression of glial glutamate transporters, independently of its anti-inflammatory effects. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
4. Interaction between interleukin-1β and type-1 cannabinoid receptor is involved in anxiety-like behavior in experimental autoimmune encephalomyelitis.
- Author
-
Gentile, Antonietta, Fresegna, Diego, Musella, Alessandra, Sepman, Helena, Bullitta, Silvia, De Vito, Francesca, Fantozzi, Roberta, Usiello, Alessandro, Maccarrone, Mauro, Mercuri, Nicola B., Lutz, Beat, Mandolesi, Georgia, and Centonze, Diego
- Subjects
CANNABINOID receptors ,ENCEPHALOMYELITIS ,ANXIETY ,MOOD (Psychology) ,INTERLEUKIN-1 ,NEURAL transmission ,LABORATORY mice ,AMPHETAMINES ,ANIMAL experimentation ,ANTIRHEUMATIC agents ,BASAL ganglia ,BEHAVIOR ,BIOLOGICAL models ,CELL receptors ,CELLULAR signal transduction ,CEREBRAL cortex ,DEMYELINATION ,EYE physiology ,MICE ,PEPTIDES ,PROTEINS ,CENTRAL nervous system stimulants ,MEMBRANE glycoproteins ,EXCITATORY amino acid antagonists ,DISEASE complications ,PHARMACODYNAMICS - Abstract
Background: Mood disorders, including anxiety and depression, are frequently diagnosed in multiple sclerosis (MS) patients, even independently of the disabling symptoms associated with the disease. Anatomical, biochemical, and pharmacological evidence indicates that type-1 cannabinoid receptor (CB1R) is implicated in the control of emotional behavior and is modulated during inflammatory neurodegenerative diseases such as MS and experimental autoimmune encephalomyelitis (EAE).Methods: We investigated whether CB1R could exert a role in anxiety-like behavior in mice with EAE. We performed behavioral, pharmacological, and electrophysiological experiments to explore the link between central inflammation, mood, and CB1R function in EAE.Results: We observed that EAE-induced anxiety was associated with the downregulation of CB1R-mediated control of striatal GABA synaptic transmission and was exacerbated in mice lacking CB1R (CB1R-KO mice). Central blockade of interleukin-1β (IL-1β) reversed the anxiety-like phenotype of EAE mice, an effect associated with the concomitant rescue of dopamine (DA)-regulated spontaneous behavior, and DA-CB1R neurotransmission, leading to the rescue of striatal CB1R sensitivity.Conclusions: Overall, results of the present investigation indicate that synaptic dysfunction linked to CB1R is involved in EAE-related anxiety and motivation-based behavior and contribute to clarify the complex neurobiological mechanisms underlying mood disorders associated to MS. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
5. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.
- Author
-
Gentile, Antonietta, Musella, Alessandra, Bullitta, Silvia, Fresegna, Diego, De Vito, Francesca, Fantozzi, Roberta, Piras, Eleonora, Gargano, Francesca, Borsellino, Giovanna, Battistini, Luca, Schubart, Anna, Mandolesi, Georgia, and Centonze, Diego
- Subjects
- *
NEURODEGENERATION , *MULTIPLE sclerosis , *ENCEPHALOMYELITIS , *EXCITATORY amino acid agents , *CENTRAL nervous system , *CELL metabolism , *ANIMAL experimentation , *ANIMALS , *ANTIGENS , *BIOLOGICAL models , *BIOLOGICAL transport , *BRAIN , *CALCIUM-binding proteins , *CELLS , *CEREBRAL cortex , *CYTOKINES , *DEMYELINATION , *HETEROCYCLIC compounds , *MICE , *MICROFILAMENT proteins , *NERVOUS system , *NEURAL conduction , *NEURONS , *PEPTIDES , *SOLUTION (Chemistry) , *T cells , *NEUROPROTECTIVE agents , *BENZYL compounds , *MEMBRANE glycoproteins , *DISEASE complications , *PHARMACODYNAMICS , *PREVENTION , *THERAPEUTICS - Abstract
Background: Data from multiple sclerosis (MS) and the MS rodent model, experimental autoimmune encephalomyelitis (EAE), highlighted an inflammation-dependent synaptopathy at the basis of the neurodegenerative damage causing irreversible disability in these disorders. This synaptopathy is characterized by an imbalance between glutamatergic and GABAergic transmission and has been proposed to be a potential therapeutic target. Siponimod (BAF312), a selective sphingosine 1-phosphate1,5 receptor modulator, is currently under investigation in a clinical trial in secondary progressive MS patients. We investigated whether siponimod, in addition to its peripheral immune modulation, may exert direct neuroprotective effects in the central nervous system (CNS) of mice with chronic progressive EAE.Methods: Minipumps allowing continuous intracerebroventricular (icv) infusion of siponimod for 4 weeks were implanted into C57BL/6 mice subjected to MOG35-55-induced EAE. Electrophysiology, immunohistochemistry, western blot, qPCR experiments, and peripheral lymphocyte counts were performed. In addition, the effect of siponimod on activated microglia was assessed in vitro to confirm the direct effect of the drug on CNS-resident immune cells.Results: Siponimod administration (0.45 μg/day) induced a significant beneficial effect on EAE clinical scores with minimal effect on peripheral lymphocyte counts. Siponimod rescued defective GABAergic transmission in the striatum of EAE, without correcting the EAE-induced alterations of glutamatergic transmission. We observed a significant attenuation of astrogliosis and microgliosis together with reduced lymphocyte infiltration in the striatum of EAE mice treated with siponimod. Interestingly, siponimod reduced the release of IL-6 and RANTES from activated microglial cells in vitro, which might explain the reduced lymphocyte infiltration. Furthermore, the loss of parvalbumin-positive (PV+) GABAergic interneurons typical of EAE brains was rescued by siponimod treatment, providing a plausible explanation of the selective effects of this drug on inhibitory synaptic transmission.Conclusions: Altogether, our results show that siponimod has neuroprotective effects in the CNS of EAE mice, which are likely independent of its peripheral immune effect, suggesting that this drug could be effective in limiting neurodegenerative pathological processes in MS. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.